Clinical Trials Sponsored by Indrayani Hospital and Cancer Institute

Total 12592 results

Shandong Cancer Hospital and Institute

Completed

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative (IMSLNB-EBCP)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Completed

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Cervical Cancer | Stomach Cancer | Breast Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Ovary Cancer | Malignancies

China
Shandong Cancer Hospital and Institute

Unknown

Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients

Chronic Hepatitis B | Dysplastic Nodule of Liver
Shandong Cancer Hospital and Institute

Unknown

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Prosthesis Survival

China
Shandong Cancer Hospital and Institute

Unknown

A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma

Glioblastoma

China
Shandong Cancer Hospital and Institute

Unknown

Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

Non Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute

Unknown

IMRT/Pemetrexed/Cisplatin in Esophageal Cancer

Esophageal Cancer

China
Shandong Cancer Hospital and Institute

Unknown

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

Liver Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | HBV | PHENYTOIN/SORAFENIB [VA Drug Interaction] | DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]

China
Shandong Cancer Hospital and Institute
Peking University Cancer Hospital & Institute

Unknown

Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy...
Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...

Unknown

Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; (IMRT)

Esophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After Esophagectomy (OSinEC)

Outcomes of Smoker and Drinker After Esophagectomy

China
Sichuan Cancer Hospital and Research Institute

Recruiting

MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer

HNSCC

China
Sichuan Cancer Hospital and Research Institute

Recruiting

The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma

HNSCC

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Ovarian Cancer

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Dose-painting Radiation for LA-NSCLC (DPRLC)

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage II

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Surveillance of Peripheral Blood of Lymphocyte and Immunocyte in Neoadjuvant Therapy Patients With Esophageal Squamous Cell Carcinoma (pLINE)

Surgery | Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Chemoradiotherapy | PD-1 Inhibitors

China
Sichuan Cancer Hospital and Research Institute

Unknown

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Lung Cancer Stage IV
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
Sichuan Cancer Hospital and Research Institute

Recruiting

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

ALK-positive Non-small Cell Lung Cancer | Real World Study

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer (UNLACC)

Safety and Efficacy
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

A Cohort Establishment Study of Total Management of Ovarian Cancer

Ovarian Cancer | Tumor of Female Reproductive System
Sichuan Cancer Hospital and Research Institute

Recruiting

A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms

Gynecologic Surgery | High-flow Nasal Cannula | Post-operative Pulmonary Complications

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer (IMCORT-2)

Non-small Cell Lung Cancer Metastatic

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.

Non-small Cell Lung Cancer | Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer (ALTER-GO-020)

Gynecological Cancer

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Apatinib | PD-1 Antibody | Transarterial Chemoembolization

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Lung Diseases | Thoracic Neoplasms | Non-small Cell Lung Cancer | Pulmonary Sarcomatoid Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Brain Metastases | ALK-positive Non-small Cell Lung Cancer | Meningeal Metastasis

China
Sichuan Cancer Hospital and Research Institute

Completed

Association Between Surgical Timing and Route of Total Hysterectomy After LEEP and Perioperative Risk in Patients With Cervical HSIL

High-Grade Squamous Intraepithelial Lesions

China
Shandong Cancer Hospital and Institute
BeiGene

Active, not recruiting

A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma (Notable-HCC)

Hepatocellular Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Completed

Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study (ECPLNMvsSLNM)

Esophageal Cancer

China
Sichuan Cancer Hospital and Research Institute

Unknown

Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction

Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Unknown

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Angiogenesis Inhibitors，Ovarian Neoplasms

China
Sichuan Cancer Hospital and Research Institute

Unknown

Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer

Lung Cancer

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Effect of 3D-printed Reconstruction System in Size of Left DLT

Cancer of Lung | Lung Isolation
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy

Postoperative Pneumonia | Postoperative Pulmonary Atelectasis | Postoperative Pulmonary Edema
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Gynecological Tumor

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute

Recruiting

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ETNT)

Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

Cervical Cancer

China
Sichuan Cancer Hospital and Research Institute

Recruiting

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Liver Diseases | Digestive System Neoplasms | Liver Neoplasms | Hepatocellular Carcinoma | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action | Protein Kinase Inhibitors | Sorafenib

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Unknown

Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy

Lung Cancer | Extensive-stage Small Cell Lung Cancer

China
Zhejiang Cancer Hospital
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Stage III Non-small-Cell Lung Cancer

China

Clinical Trials Sponsored by Indrayani Hospital and Cancer Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations